Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family practice physicians, internists, pediatricians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

• Diagnose patients with influenza infection by using guideline recommendations and best practices.
• Distinguish antiviral treatments for influenza based on their efficacy, safety, and ability to reduce viral shedding.
• Select the most appropriate treatment for patients diagnosed with influenza who are at normal or high risk for complications.
• Assess the use of antiviral prophylaxis in people who have been exposed to influenza infection.

Activity Description

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets as well as different mechanisms of action provide multiple therapeutic options, and hold promise in improving treatment effectiveness. Family physicians and advanced practice clinicians are integral for the expedient management of patients with flu. In this Wheel of Knowledge Challenge, your knowledge will be tested on the latest updates in diagnosing and managing influenza.

Activity Chair

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 1/15/2021 to 1/14/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid from 1/15/2021 to 1/14/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201758.

This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124677. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This enduring material is approved for 1 year from the date of original release, January 15, 2021 through January 14, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hours Certificate, or AAPA Category 1 CME Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family practice physicians, internists, pediatricians, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

• Diagnose patients with influenza infection by using guideline recommendations and best practices.
• Distinguish antiviral treatments for influenza based on their efficacy, safety, and ability to reduce viral shedding.
• Select the most appropriate treatment for patients diagnosed with influenza who are at normal or high risk for complications.
• Assess the use of antiviral prophylaxis in people who have been exposed to influenza infection.

Activity Description

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets as well as different mechanisms of action provide multiple therapeutic options, and hold promise in improving treatment effectiveness. Family physicians and advanced practice clinicians are integral for the expedient management of patients with flu. In this Wheel of Knowledge Challenge, your knowledge will be tested on the latest updates in diagnosing and managing influenza.

Activity Chair

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Linda A. Giarraputo, PA-C
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

The AAFP has reviewed Incorporating Influenza Treatment Paradigms that Reduce Complications: A Wheel of Knowledge Challenge and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 1/15/2021 to 1/14/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid from 1/15/2021 to 1/14/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201758.

This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20124677. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This enduring material is approved for 1 year from the date of original release, January 15, 2021 through January 14, 2022.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hours Certificate, or AAPA Category 1 CME Credit Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
• Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.

Agenda

Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Treating Influenza in Pediatric Patients With Rheumatic Disease
Stan L. Block, MD, FAAP

Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Activity Chair

Timothy Beukelman, MD, MS, MSCE
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL

Disclosure:
Consulting Fee: Novartis, UCB

Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi

Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists, pediatric rheumatologists, pediatricians, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

• Utilize evidence-based recommendations to improve earlier detection and treatment of pediatric patients with influenza and rheumatic disease.
• Incorporate the most appropriate therapeutic regimen in pediatric patients with influenza who are immunosuppressed and at high risk for complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. There is a need for better treatments for patients with influenza, preventive measures, and better mitigation for the impact associated with a pandemic, especially in high-risk pediatric patients who have comorbid illnesses or are immunocompromised. Children with rheumatic diseases receiving immunosuppressive therapy are a high-risk group for influenza. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving the treatment of these patients. In this educational activity, expert clinicians will discuss the latest information on diagnosing and treating children with rheumatic disease who have influenza.

Agenda

Diagnosing Influenza: Following the Recommendations
Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Treating Influenza in Pediatric Patients With Rheumatic Disease
Stan L. Block, MD, FAAP

Case Presentations
Timothy Beukelman, MD, MS, MSCE; Stan L. Block, MD, FAAP; and Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ

Activity Chair

Timothy Beukelman, MD, MS, MSCE
Associate Professor of Pediatrics
University of Alabama at Birmingham
Birmingham, AL

Disclosure:
Consulting Fee: Novartis, UCB

Faculty

Stan L. Block, MD, FAAP
Professor of Clinical Pediatrics
University of Louisville
University of Kentucky
President, Kentucky Pediatric and Adult Research
Bardstown, KY

Disclosure:
Contracted Research: AstraZeneca, Genentech, GlaxoSmithKline, Sanofi, Shionogi

Margot Savoy, MD, MPH, FAAFP, FABC, FAAPL, CPE, CMQ
Chair, Family and Community Medicine
Associate Professor, Family and Community Medicine
Chief Quality Officer
Lewis Katz School of Medicine
Temple University
Philadelphia, PA

Disclosure:
Honorarium: Merck Manual
Board of Directors: AAFP

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Medical Writer
Valerie Zimmerman, PhD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

The articles in this monograph were composed by Medical Writer Valerie Zimmerman, PhD, based on the presentations of Drs. Beukelman, Block, and Savoy during a virtual expert panel discussion held on September 3, 2020. The monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, December 31, 2020 to December 30, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering at least 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

• Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
• Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

• Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
• Describe how to evaluate quality-of-life issues and psychosocial comorbidities in patients with atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world chronic rhinosinusitis with nasal polyps patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

• Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
• Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com. 

Activity Details

Provided By

This activity is jointly provided by Global Education Group and RMEI Medical Education, LLC.

Target Audience

The educational design of this activity addresses the needs of physicians who specialize in allergy/immunology, dermatology, otolaryngology, pulmonology, and primary care.

Learning Objectives

After completing this activity, the participant should be better able to:

• Identify patients with type 2 inflammatory diseases who are eligible for step-up therapies, including new and emerging biologics
• Describe how to work with a multidisciplinary team to develop a treatment strategy for patients with multiple coexisting atopic diseases

Activity Description

In this interactive panel discussion, 3 multidisciplinary clinical opinion leaders discuss management solutions for a real-world asthma patient case that was selected from a community-based clinician submission.

Statement of Educational Need

Advances in understanding the pathophysiology of atopic diseases highlight the importance and commonality of underlying type 2 inflammation in a range of diseases like asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Key drivers of type 2 inflammation have been identified, with IL-4 and IL-13 playing a central role. In the last few years, biologics targeting type 2 inflammation have emerged as effective treatment options for patients with atopic diseases, particularly in people with moderate-to-severe disease. Because of the relative novelty of these treatments, healthcare professionals should be aware of the pathophysiology of disease, as well as the efficacy, safety, and tolerability of biologics, the rationale for use, and how to incorporate these treatments into management of appropriate patients. 

Faculty

Peter A. Lio, MD, FAAD
Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Joseph K. Han, MD
Professor, EVMS
Chief, Division of Rhinology and Endoscopic Sinus-Skull Base Surgery
Chief, Division of Allergy
President Elect, ARS
Chair Elect, AAAAI, RROAC
Eastern Virginia Medical School
Norfolk, VA

Anju T. Peters, MD, MS
Professor, Medicine
Division of Allergy-Immunology
Director, Clinical Research
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Peter Lio, MD, FAAD
Consultant/Independent Contractor: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Grant/Research Support: AbbVie, National Eczema Association, Regeneron/Sanofi Genzyme.
Honoraria: AbbVie, Amyris, AObiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Speaker’s Bureau: Galderma, L’Oréal, Pfizer, Regeneron/Sanofi Genzyme.
Advisory Board: AbbVie, Amyris, AOBiome, Arbonne, Bodewell, Burt’s Bees, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience/Altus Labs (Stock Options), Galderma, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharmaceuticals, Level Ex, Menlo Therapeutics, Micreos (Stock Options), Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB, Unilever, Verrica, Yobee Care (Stock Options).
Stock Shareholder: Altus Labs, Micreos, YoBee.
Other Royalty: Theraplex AIM (OTC product) Royalties. 

Joseph K. Han, MD
Consultant/Independent Contractor: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi Regeneron.

Anju T. Peters, MD, MS
Grant/Research Support: AstraZeneca, Optinose (Research Support is to Institution)
Advisory Board: AstraZeneca, GlaxoSmithKline, Optinose, Sanofi Regeneron.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 

Lindsay Borvansky has nothing to disclose.
Andrea Funk has nothing to disclose.
Liddy Knight has nothing to disclose.
Ashley Cann has nothing to disclose.
Deborah Liao has nothing to disclose.
Sharon Powell has nothing to disclose.
Elizabeth Johnson has nothing to disclose. 

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and RMEI Medical Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians. 

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

There is no fee for this educational activity. 

This activity was released on December 21, 2020 and is valid for one year. Requests for credit must be made no later than December 20, 2021.

In order to receive credit for this activity, the participant must:

• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the activity post-test (score 75% or higher) and evaluation.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and RMEI Medical Education, LLC do not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.